GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

olokizumab   Click here for help

GtoPdb Ligand ID: 11601

Synonyms: CDP 6038 | CDP-6038 | CDP6038
Compound class: Antibody
Comment: Olokizumab (CDP 6038) is a clinical stage anti-IL-6 monoclonal antibody [3], that was designed for potential to treat autoimmune diseases. The antibody blocks assembly of the hexameric IL-6/IL-6 α-receptor/gp130 (IL6ST) complex that is required for signal transduction.
No information available.
Summary of Clinical Use Click here for help
UCB Pharma advanced olokizumab into clinical evaluation in rheumatoid arthritis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01463059 Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy Phase 2 Interventional UCB Pharma 4
NCT01262794 Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects Phase 1 Interventional UCB Pharma 2
NCT01296711 Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056 Phase 2 Interventional UCB Pharma 1
NCT01242488 Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy Phase 2 Interventional UCB Pharma